Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
labor%20induction
LABOR INDUCTION
Labor induction is when an external agent is employed to stimulate contractions before the onset of spontaneous labor.
Labor augmentation uses the same techniques as labor induction but uterine contractions (frequency, duration and strength) are enhanced once labor has started.
Labor induction is generally indicated when the benefits of delivery outweigh the risks of continuing the pregnancy.
Women at 42 weeks of gestation who chose not to undergo labor induction should be monitored more often with at least twice-weekly assessment of fetal well-being (cardiotocography & estimation of maximum amniotic pool depth by ultrasound).

Labor%20induction Management

Monitoring

  • It is recommended that facilities for continuous uterine and fetal heart rate (HR) monitoring are available during labor induction
    • Continuous uterine activity and fetal HR monitoring is recommended if Prostaglandin E2 (PGE2) or Oxytocin is to be administered
    • Maternal pulse, blood pressure (BP), uterine contractions and fetal heart tone should be assessed and documented
  • Reassess Bishop score (after 6 hours for vaginal tablet or gel for 24 hours for controlled-release pessary)
  • Uterine tachysystole
    • Monitor for uterine tachysystole and institute appropriate management if it occurs
    • Patients should never be left unattended while Oxytocin is being administered
  • Appropriate measures if uterine tachysystole occurs
    • Discontinue Oxytocin or remove any remaining Prostaglandin preparation (do not irrigate cervix/vagina) and apply supportive/resuscitative measures if:
      • Uterine contractions exceed 5 in a 10-minute period (tachysystole) or
      • Uterine contractions last longer than 90-120 seconds
      • Fetal HR decelerates significantly; non-reassuring fetal heart rate tracing
    • For persistence of excessive uterine activity, begin tocolysis with
      • Terbutaline 250 mcg subcutaneous/intravenous (SC/IV) or
      • Glyceryl trinitrate 50-200 mcg IV or 1-2 sublingual spray (400-800 mcg) is recommended
      • Place patient in the lateral position, oxygen (O2) by face mask may be administered
    • Oxytocin may be restarted at 1/2 the dose if resuscitation is successful
  • Pain relief during induction of labor
    • Patients should be informed of the possibility of induced labor being more painful than spontaneous labor
    • Pain relief should be offered depending on what is appropriate for the patient and her pain
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Lower joint replacement risk yet another benefit of statins
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Migraine a risk factor for dementia?
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Daily alcohol intake, certain drugs tied to liver abnormalities in PsA patients
30 Jun 2020
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab + chemo improves PFS in previously untreated, advanced TNBC
Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.